On September 24, 2026, Rocket Pharmaceuticals is trading at $2.71, down 10%, amid continued pressure across biotechnology and growth stocks.
- The Nasdaq is down 0.79%, and XBI is down 2.04%; the 10-year Treasury yield has risen to approximately 5.14%, raising concerns about borrowing costs and valuation pressure.
- No fresh company-specific catalyst was identified. The latest major news was FDA alignment announced September 15 concerning the RP-A501 Danon disease trial, which does not explain today’s decline.